NEW YORK, September 2, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET....
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, September 1, 2026 – Immunic, Inc. (Nasdaq:...
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by...
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, August 10, 2026 – Immunic , Inc. (Nasdaq:...
NEW YORK, July 9, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum....
NEW YORK, June 10, 2026 – Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit....
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium’s Favorable Safety and Tolerability Profile;...
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic’s Transition Toward a Commercial-Stage Multiple Sclerosis Company – NEW YORK, May 27, 2026 – Immunic, Inc. (Nasdaq:...
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 – Immunic, Inc. (Nasdaq:...
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer – – Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 – – Raised $200 Million in an Oversubscribed Private Placement,...
NEW YORK, April 30, 2026 – Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe ....
– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development – NEW YORK, April 28, 2026 – Immunic, Inc. (Nasdaq:...
NEW YORK, April 23, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the “Company” or “Immunic”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026....